• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项关于德黑兰(伊朗)住院 COVID-19 患者急性肾损伤和全因死亡率的危险因素的前瞻性研究。

A Prospective Study on Risk Factors for Acute Kidney Injury and All-Cause Mortality in Hospitalized COVID-19 Patients From Tehran (Iran).

机构信息

Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Padua University, Padua, Italy.

出版信息

Front Immunol. 2022 Jul 8;13:874426. doi: 10.3389/fimmu.2022.874426. eCollection 2022.

DOI:10.3389/fimmu.2022.874426
PMID:35928822
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9345117/
Abstract

BACKGROUND

Several reports suggested that acute kidney injury (AKI) is a relatively common occurrence in hospitalized COVID-19 patients, but its prevalence is inconsistently reported across different populations. Moreover, it is unknown whether AKI results from a direct infection of the kidney by SARS-CoV-2 or it is a consequence of the physiologic disturbances and therapies used to treat COVID-19. We aimed to estimate the prevalence of AKI since it varies by geographical settings, time periods, and populations studied and to investigate whether clinical information and laboratory findings collected at hospital admission might influence AKI incidence (and mortality) in a particular point in time during hospitalization for COVID-19.

METHODS

Herein we conducted a prospective longitudinal study investigating the prevalence of AKI and associated factors in 997 COVID-19 patients admitted to the Baqiyatallah general hospital of Tehran (Iran), collecting both clinical information and several dates (of: birth; hospital admission; AKI onset; ICU admission; hospital discharge; death). In order to examine how the clinical factors influenced AKI incidence and all-cause mortality during hospitalization, survival analysis using the Cox proportional-hazard models was adopted. Two separate multiple Cox regression models were fitted for each outcome (AKI and death).

RESULTS

In this group of hospitalized COVID-19 patients, the prevalence of AKI was 28.5% and the mortality rate was 19.3%. AKI incidence was significantly enhanced by diabetes, hyperkalemia, higher levels of WBC count, and blood urea nitrogen (BUN). COVID-19 patients more likely to die over the course of their hospitalization were those presenting a joint association between ICU admission with either severe COVID-19 or even mild/moderate COVID-19, hypokalemia, and higher levels of BUN, WBC, and LDH measured at hospital admission. Diabetes and comorbidities did not increase the mortality risk among these hospitalized COVID-19 patients.

CONCLUSIONS

Since the majority of patients developed AKI after ICU referral and 40% of them were admitted to ICU within 2 days since hospital admission, these patients may have been already in critical clinical conditions at admission, despite being affected by a mild/moderate form of COVID-19, suggesting the need of early monitoring of these patients for the onset of eventual systemic complications.

摘要

背景

有几项报告表明,急性肾损伤(AKI)在住院的 COVID-19 患者中较为常见,但不同人群的报告结果并不一致。此外,尚不清楚 AKI 是否是由 SARS-CoV-2 直接感染肾脏引起,还是由用于治疗 COVID-19 的生理紊乱和治疗方法引起的。我们旨在估计 AKI 的患病率,因为它因地理位置、时间段和研究人群而异,并研究在 COVID-19 住院期间的特定时间点,入院时的临床信息和实验室检查结果是否会影响 AKI 的发生率(和死亡率)。

方法

本研究进行了一项前瞻性纵向研究,调查了 997 例入住德黑兰巴盖亚塔勒医院(伊朗)的 COVID-19 患者的 AKI 患病率及相关因素,收集了临床信息和多个日期(出生日期、入院日期、AKI 发病日期、入住 ICU 日期、出院日期、死亡日期)。为了研究临床因素如何影响住院期间 AKI 发生率和全因死亡率,采用 Cox 比例风险模型进行生存分析。针对每个结局(AKI 和死亡)拟合了两个独立的多 Cox 回归模型。

结果

在这组住院 COVID-19 患者中,AKI 的患病率为 28.5%,死亡率为 19.3%。糖尿病、高钾血症、较高的白细胞计数和血尿素氮(BUN)水平显著增加了 AKI 的发生率。在住院期间更有可能死亡的 COVID-19 患者是那些同时存在 ICU 入院与重症 COVID-19 或甚至轻度/中度 COVID-19、低钾血症以及入院时较高的 BUN、白细胞计数和 LDH 水平的患者。糖尿病和合并症并没有增加这些住院 COVID-19 患者的死亡风险。

结论

由于大多数患者在转入 ICU 后出现 AKI,且其中 40%的患者在入院后 2 天内转入 ICU,这些患者在入院时可能已经处于危急的临床状况,尽管他们患有轻度/中度 COVID-19,这表明需要对这些患者进行早期监测,以防止出现全身并发症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6a4/9345117/4438fe886a9e/fimmu-13-874426-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6a4/9345117/9546f00da5ee/fimmu-13-874426-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6a4/9345117/0bc8780a4ee7/fimmu-13-874426-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6a4/9345117/278e24a3a428/fimmu-13-874426-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6a4/9345117/37cd7e1cc5bb/fimmu-13-874426-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6a4/9345117/4438fe886a9e/fimmu-13-874426-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6a4/9345117/9546f00da5ee/fimmu-13-874426-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6a4/9345117/0bc8780a4ee7/fimmu-13-874426-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6a4/9345117/278e24a3a428/fimmu-13-874426-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6a4/9345117/37cd7e1cc5bb/fimmu-13-874426-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6a4/9345117/4438fe886a9e/fimmu-13-874426-g005.jpg

相似文献

1
A Prospective Study on Risk Factors for Acute Kidney Injury and All-Cause Mortality in Hospitalized COVID-19 Patients From Tehran (Iran).一项关于德黑兰(伊朗)住院 COVID-19 患者急性肾损伤和全因死亡率的危险因素的前瞻性研究。
Front Immunol. 2022 Jul 8;13:874426. doi: 10.3389/fimmu.2022.874426. eCollection 2022.
2
The Risk Factors and Clinical Outcomes Associated with Acute Kidney Injury in Patients with COVID-19: Data from a Large Cohort in Iran.与 COVID-19 患者急性肾损伤相关的危险因素和临床结局:来自伊朗大型队列的数据。
Kidney Blood Press Res. 2021;46(5):620-628. doi: 10.1159/000517581. Epub 2021 Jul 27.
3
Acute Kidney Injury in COVID-19 Patients: An Inner City Hospital Experience and Policy Implications.新型冠状病毒肺炎患者的急性肾损伤:城市内医院的经验及政策影响。
Am J Nephrol. 2020;51(10):786-796. doi: 10.1159/000511160. Epub 2020 Oct 2.
4
Use of an extended KDIGO definition to diagnose acute kidney injury in patients with COVID-19: A multinational study using the ISARIC-WHO clinical characterisation protocol.使用扩展的 KDIGO 定义诊断 COVID-19 患者的急性肾损伤:一项使用 ISARIC-WHO 临床特征协议的多国研究。
PLoS Med. 2022 Apr 20;19(4):e1003969. doi: 10.1371/journal.pmed.1003969. eCollection 2022 Apr.
5
Impact of hospital-acquired acute kidney injury on Covid-19 outcomes in patients with and without chronic kidney disease: a multicenter retrospective cohort study.医院获得性急性肾损伤对合并和不合并慢性肾脏病的新冠肺炎患者结局的影响:一项多中心回顾性队列研究。
Turk J Med Sci. 2021 Jun 28;51(3):947-961. doi: 10.3906/sag-2011-169.
6
Acute kidney injury in patients with COVID-19 in the intensive care unit: evaluation of risk factors and mortality in a national cohort.新冠肺炎患者 ICU 中急性肾损伤:全国队列研究中危险因素和死亡率评估。
BMJ Open. 2022 Jun 23;12(6):e059046. doi: 10.1136/bmjopen-2021-059046.
7
Acute Kidney Injury Outcome in COVID-19 Patients.新型冠状病毒肺炎患者急性肾损伤结局。
Iran J Kidney Dis. 2022 Jan;1(1):44-51.
8
Risk factors, predictions, and progression of acute kidney injury in hospitalized COVID-19 patients: An observational retrospective cohort study.COVID-19 住院患者急性肾损伤的风险因素、预测因素和进展:一项观察性回顾性队列研究。
PLoS One. 2021 Sep 29;16(9):e0257253. doi: 10.1371/journal.pone.0257253. eCollection 2021.
9
Acute Kidney Injury at Hospital Admission for SARS-CoV-2 Infection as a Marker of Poor Prognosis: Clinical Implications for Triage Risk Stratification.SARS-CoV-2 感染住院时的急性肾损伤是预后不良的标志物:用于分诊风险分层的临床意义。
Kidney Blood Press Res. 2022;47(2):147-150. doi: 10.1159/000518271. Epub 2022 Jan 10.
10
Hypophosphatemia is an independent risk factor for AKI among hospitalized patients with COVID-19 infection.低磷血症是 COVID-19 感染住院患者发生 AKI 的独立危险因素。
Ren Fail. 2021 Dec;43(1):1329-1337. doi: 10.1080/0886022X.2021.1979039.

引用本文的文献

1
Global geographic and socioeconomic disparities in COVID-associated acute kidney injury: a systematic review and meta-analysis.新冠相关急性肾损伤的全球地理和社会经济差异:一项系统综述和荟萃分析。
J Glob Health. 2025 Jul 25;15:04166. doi: 10.7189/jogh.15.04166.
2
Surveying haemoperfusion impact on COVID-19 from machine learning using Shapley values.基于 Shapley 值的机器学习对 COVID-19 血液灌流影响的调查。
Inflammopharmacology. 2024 Aug;32(4):2285-2294. doi: 10.1007/s10787-024-01494-z. Epub 2024 May 19.
3
Development and validation of a prognostic model based on clinical laboratory biomarkers to predict admission to ICU in Omicron variant-infected hospitalized patients complicated with myocardial injury.

本文引用的文献

1
COVID-19 and Acute Kidney Injury: A Systematic Review.新型冠状病毒肺炎与急性肾损伤:一项系统综述
Front Med (Lausanne). 2022 Apr 4;9:705908. doi: 10.3389/fmed.2022.705908. eCollection 2022.
2
Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.估算 2021 年 11 月 14 日前全球、区域和国家的 SARS-CoV-2 日感染和累计感染人数:一项统计分析。
Lancet. 2022 Jun 25;399(10344):2351-2380. doi: 10.1016/S0140-6736(22)00484-6. Epub 2022 Apr 8.
3
Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage.
基于临床实验室生物标志物的预测奥密克戎变异株感染住院合并心肌损伤患者入住 ICU 的预后模型的建立与验证。
Front Immunol. 2024 Feb 1;15:1268213. doi: 10.3389/fimmu.2024.1268213. eCollection 2024.
4
Factors Affecting Mortality in Elderly Hypertensive Hospitalized Patients with COVID-19: A Retrospective Study.影响 COVID-19 老年高血压住院患者死亡率的因素:一项回顾性研究。
Clin Interv Aging. 2023 Nov 20;18:1905-1921. doi: 10.2147/CIA.S431271. eCollection 2023.
5
Identification of berberine as a potential therapeutic strategy for kidney clear cell carcinoma and COVID-19 based on analysis of large-scale datasets.基于大规模数据集的分析,鉴定小檗碱作为治疗肾透明细胞癌和 COVID-19 的潜在策略。
Front Immunol. 2023 Mar 23;14:1038651. doi: 10.3389/fimmu.2023.1038651. eCollection 2023.
6
Enhancing the expression of a key mitochondrial enzyme at the inception of ischemia-reperfusion injury can boost recovery and halt the progression of acute kidney injury.在缺血再灌注损伤开始时增强一种关键线粒体酶的表达,可以促进恢复并阻止急性肾损伤的进展。
Front Physiol. 2023 Feb 8;14:1024238. doi: 10.3389/fphys.2023.1024238. eCollection 2023.
7
From waste to wealth: Repurposing slaughterhouse waste for xenotransplantation.变废为宝:将屠宰场废弃物重新用于异种移植。
Front Bioeng Biotechnol. 2023 Feb 3;11:1091554. doi: 10.3389/fbioe.2023.1091554. eCollection 2023.
8
Persistence of Symptoms 15 Months since COVID-19 Diagnosis: Prevalence, Risk Factors and Residual Work Ability.新冠病毒病确诊后15个月症状持续情况:患病率、危险因素及残余工作能力
Life (Basel). 2022 Dec 29;13(1):97. doi: 10.3390/life13010097.
理解 SARS-CoV-2 通过宿主中的 ACE2 入侵的可能途径与多个器官损伤有关。
Infect Genet Evol. 2022 Apr;99:105254. doi: 10.1016/j.meegid.2022.105254. Epub 2022 Feb 23.
4
Kidney Injury in COVID-19: Epidemiology, Molecular Mechanisms and Potential Therapeutic Targets.COVID-19 相关肾损伤:流行病学、分子机制及潜在治疗靶点。
Int J Mol Sci. 2022 Feb 17;23(4):2242. doi: 10.3390/ijms23042242.
5
Gender and Ethnic Disparities of Acute Kidney Injury in COVID-19 Infected Patients: A Literature Review.新型冠状病毒感染患者急性肾损伤的性别和种族差异:文献综述。
Front Cell Infect Microbiol. 2022 Jan 13;11:778636. doi: 10.3389/fcimb.2021.778636. eCollection 2021.
6
Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies.COVID-19 导致肾损伤的机制和当前的药物治疗方法。
Inflamm Res. 2022 Jan;71(1):39-56. doi: 10.1007/s00011-021-01520-8. Epub 2021 Nov 21.
7
Acute kidney injury in COVID-19: multicentre prospective analysis of registry data.新型冠状病毒肺炎相关急性肾损伤:登记数据的多中心前瞻性分析
Clin Kidney J. 2021 Mar 27;14(11):2356-2364. doi: 10.1093/ckj/sfab071. eCollection 2021 Nov.
8
Acute Kidney Injury and Renal Replacement Therapy in COVID-19 Versus Other Respiratory Viruses: A Systematic Review and Meta-Analysis.新型冠状病毒肺炎与其他呼吸道病毒所致急性肾损伤及肾脏替代治疗:一项系统评价与Meta分析
Can J Kidney Health Dis. 2021 Oct 30;8:20543581211052185. doi: 10.1177/20543581211052185. eCollection 2021.
9
Do high-dose corticosteroids improve outcomes in hospitalized COVID-19 patients?大剂量皮质类固醇能否改善住院 COVID-19 患者的结局?
J Med Virol. 2022 Jan;94(1):372-379. doi: 10.1002/jmv.27357. Epub 2021 Oct 8.
10
Gastrointestinal cancers, ACE-2/TMPRSS2 expression and susceptibility to COVID-19.胃肠道癌症、ACE-2/TMPRSS2表达与对2019冠状病毒病的易感性
Cancer Cell Int. 2021 Aug 16;21(1):431. doi: 10.1186/s12935-021-02129-x.